## **CLAIMS**

20

120 1 3

- A wound care device for local treatment of pain in a wound, said device comprising an active pain relieving agent, the device being constructed in such a manner that the pain killing agent is released to the wound in such a way that
  substantially no effective systemic plasma concentration of the pain killing agent can be found and wherein a majority of said pain killing agent is in direct contact with the wound.
- 2. A wound care device for local treatment of pain in a wound, said device comprising an active pain relieving composition, said composition is a pain killing agent, wherein the amount of pain killing agent in the device is below the daily unit dose for systemic treatment and wherein a majority of said pain killing agent is in direct contact with the wound.
- 3. A device according to any of the preceding claims, wherein the pain-killing agent is an anti-inflammatory pain-killing agent.
  - 4. A device according to any of the preceding claims, wherein the device has a maximum absorption of 0,2 g/cm<sup>2</sup>.
  - 5. A device according to any of the preceding claims, wherein the device is substantially non-absorbent.
- 6. A device according to any of the preceding claims, wherein the release of the
  pain-killing agent is substantially independent of the amount of wound exudate.
  - 7. A device according to any of the preceding claims, wherein at least 50% w/w of the pain-killing agent is released during the first 24 hours after application.
- 30 8. A device according to any of the preceding claims, wherein at least 50% w/w of the pain-killing agent is released during the first 12 hours after application.
  - 9. A device according to any of the preceding claims, wherein at least 50% w/w of the pain-killing agent is released during the first 6 hours after application.

- 10. A device according to any of the preceding claims, wherein at least 75% w/w of the pain-killing agent is released during the first 24 hours after application.
- 5 11. A device according to any of the preceding claims, wherein at least 75% w/w of the pain-killing agent is released during the first 12 hours after application.
  - 12. A device according to any of the preceding claims, wherein at least 75% w/w of the pain-killing agent is released during the first 6 hours after application.
  - 13. A device according to any of the preceding claims, wherein at least 90% w/w of the pain-killing agent is released during the first 24 hours after application.
- 14. A device according to any of the preceding claims, wherein at least 90% w/w of the pain-killing agent is released during the first 12 hours after application.
  - 15. A device according to any of the preceding claims, wherein at least 90% w/w of the pain-killing agent is released during the first 6 hours after application.
- 20 16. A device according to any of the preceding claims, wherein the device comprises one or more components selected from the group of PVP, PVA, polylactic acids, polysaccharides such as carboxy methyl cellulose, hydroxymethyl cellulose, chitosan, alginate, or polyacrylic acids, methacrylates, silicones, styrene-isoprene-styrene mixtures, vaseline, glycols such as PEG or PEG/PPG mixtures or polyurethane.
  - 17. A device according to any of the preceding claims, wherein the amount of pain killing agent is less than 75% of the daily unit dose for systemic treatment using the agent.
  - 18. A device according to any of the preceding claims, wherein the amount of pain killing agent is less than 50% of the daily unit dose for systemic treatment using the agent.

30

10

🕻 ، المندة

62. 4 . 3

- 19. A device according to any of the preceding claims, wherein the pain-killing agent is a NSAID.
- 20. A device according to any of the preceding claims, wherein the pain-killing 5 agent is ibuprofen.
- 21. A method of treating pain at a wound site comprising applying to the wound a wound care device comprising an active pain relieving composition, said composition is an anti-inflammatory pain killing agent, wherein the amount of pain killing agent in the device is below the daily unit dose for systemic treatment and wherein a majority of the pain killing agent is brought into direct contact with the wound.